CDK9 inhibitors in acute myeloid leukemia

Silvia Boffo; Angela Damato; Luigi Alfano; Antonio Giordano

doi:10.1186/s13046-018-0704-8

CDK9 inhibitors in acute myeloid leukemia

Silvia Boffo, Angela Damato, Luigi Alfano, Antonio Giordano

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Review article

Abstract

Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.

Original language	English
Article number	36
Journal	Journal of Experimental and Clinical Cancer Research
Volume	37
Issue number	1
DOIs	https://doi.org/10.1186/s13046-018-0704-8
Publication status	Published - Feb 23 2018

Fingerprint

Keywords

Acute myeloid leukemia
CDK9 inhibitor
MCL-1
MYC
P-TEFb
Positive transcription elongation factor b

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

Boffo, S., Damato, A., Alfano, L., & Giordano, A. (2018). CDK9 inhibitors in acute myeloid leukemia. Journal of Experimental and Clinical Cancer Research, 37(1), [36]. https://doi.org/10.1186/s13046-018-0704-8

@article{69065c996ecd42e2b478e1695445107c,

title = "CDK9 inhibitors in acute myeloid leukemia",

abstract = "Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.",

keywords = "Acute myeloid leukemia, CDK9 inhibitor, MCL-1, MYC, P-TEFb, Positive transcription elongation factor b",

author = "Silvia Boffo and Angela Damato and Luigi Alfano and Antonio Giordano",

year = "2018",

month = feb

day = "23",

doi = "10.1186/s13046-018-0704-8",

language = "English",

volume = "37",

journal = "Journal of Experimental and Clinical Cancer Research",

issn = "0392-9078",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - CDK9 inhibitors in acute myeloid leukemia

AU - Boffo, Silvia

AU - Damato, Angela

AU - Alfano, Luigi

AU - Giordano, Antonio

PY - 2018/2/23

Y1 - 2018/2/23

N2 - Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.

AB - Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and rational combinations. Targeting the cyclin-dependent kinase 9 (CDK9) pathway, which is dysregulated in AML, is an attractive approach. Inhibition of CDK9 leads to downregulation of cell survival genes regulated by super enhancers such as MCL-1, MYC, and cyclin D1. As CDK9 inhibitors are nonselective, predictive biomarkers that may help identify patients most likely to respond to CDK9 inhibitors are now being utilized, with the goal of improving efficacy and safety.

KW - Acute myeloid leukemia

KW - CDK9 inhibitor

KW - MCL-1

KW - MYC

KW - P-TEFb

KW - Positive transcription elongation factor b

UR - http://www.scopus.com/inward/record.url?scp=85042503905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042503905&partnerID=8YFLogxK

U2 - 10.1186/s13046-018-0704-8

DO - 10.1186/s13046-018-0704-8

M3 - Review article

AN - SCOPUS:85042503905

VL - 37

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 36

ER -

Access to Document

10.1186/s13046-018-0704-8